The Nanoparticle Drug Delivery Market : Market Research Report

The Nanoparticle Drug Delivery Market

Published: Aug. 1, 2007 - 300 Pages

EXECUTIVE SUMMARY
MARKET FORECAST
INTRODUCTION: Nanopharmaceuticals; Nanotechnology In Drug Delivery; Nanobiotechnology In Drug Delivery; Other Applications For Nanomaterials In The Medical And Pharmaceutical Sector; Trends And Needs; Roadmap; Nanotechnology Influence In Pharmaceutical Value Chain
ANALYTICAL TECHNIQUES FOR NANOPARTICLE DRUG DELIVERY: Properties; Production Of Nanoparticles; Measuring Dispersion Of Nanoparticles; Analysis Of Carrier Systems
NANOPARTICLES AS DRUG CARRIERS: Use Of Nanoparticles In Drug Delivery; Overview On The Types Of Nanoparticles In Drug Delivery; The First Nanoparticle Drug Delivery System Reaches The Market; Present And Future Applications
PROJECTED PRODUCT PIPELINE FOR NANOPARTICLES IN DRUG DELIVERY MARKET: Overview Of Nanoparticle Drug Delivery System (DDS) In Various Applications; Available Applications Of Nanoparticles In Drug Delivery
DRUG DELIVERY CHALLENGES -- WHY DRUG DELIVERY & WHY NANOPARTICLES: The Need For Better Drug Therapy; The Need For Drug Solubility; The Need For Site-Specific And Organ-Specific In Function; Drivers And Opportunities For Nanoparticle Drug Delivery; The Aim Of Drug Targeting; Reasons Why The Drug Delivery Market Is Rapidly Expanding
MARKET DRIVERS FOR ENHANCED DRUG DELIVERY: The Advantages Of Using Polymeric Nanoparticles (Pnps) In Drug Delivery; Expanding Governmental Funding Drives The Nanobiotechnology Market; How Drug Companies Are Reacting To This Expansion
FUTURE BARRIERS AND CHALLENGES: Big Pharmaceutical Companies Reluctant To Invest In Untried Technologies; Lack Of Regulatory Case Law; Long Admission Procedures Including For Example Several Clinical Trials; A Need For Rapid Screening Methods; Scalability Of Nanoparticle Production; An Urgent Need For Analytical Methods; A Need For The Further Investigation Of Nanoparticles; The Potential Toxicity Of Engineered Nanoparticles Is An Unsolved Issue And Still Needs To Be Dealt With; The Future Of Nano And Bio Collaborations Is Promising
NANOPARTICLE ADDED VALUE IN DRUG DELIVERY: Case Study -- University Of Michigan’s Nanoparticle-Based Pain Relief Study For Military Battlefield Use; Case Study -- Acusphere’s Hydrophobic Drug Delivery System (Hdds™) For Reformulation Of Hydrophobic Drugs; Case Study -- Imarx’s Hydroplex™ Platform For Delivering Hydrophobic Drugs; Case Study - Alpharx’s Nanoparticle Drug Delivery Platform For Antibiotic Drugs; Case Study - Cytrx’s Rnai Nanoparticle Delivery Technology For Rnai Therapeutics
INVESTING IN NANOPARTICLE-ENABLED DRUG DELIVERY INDUSTRY: Case Study - Nanotherapeutics’ Commercialisation Strategy; Business Summary; Technology Core Competency; Commercialisation Strategy; Available Market; Case Study - How Can Nanovindex’s Nanoparticle Hydrogel Composites Add Value For Drug Delivery Investors; Business Summary; Technology Core Competency; How Nanoparticles Add Value For Investors In Drug Delivery Companies; Commercialization Strategy; Available Market; Case Study -- Keystone Nano’s Molecular Dots (Mds) Commercialisation Strategy; Business Summary; Technology Core Competency; How Nanoparticles Add Value For Investors In Drug Delivery Companies; Commercialisation Strategy; Available Market; Intellectual Property; Case Study - Nanocarrier’s Proteins Nanoencapsulation Seeking Out Big Biotech Business; Business summary; Technology Core Competency; How Nanoparticles Add Value For Investors In Drug Delivery Companies; Commercialisation Strategy; Available Market; Case Study -- Nanobiomagnetics’ Business Model For Organ-Assisting-Device (Oad) Technologies; Business Summary; Technology Core Competency; How Nanoparticles Add Value For Investors In Drug Delivery Companies; Commercialisation Strategy; Intellectual Property; Case Study - How Can Avidimer Therapeutics’ Avidimers Platform Technology Add Value For Drug Delivery Investors; Business Summary; Technology Core Competency; How Nanoparticles Add Value For Investors In Drug Delivery Companies; Commercialisation Strategy; Case Study -- Capsulution’s Commercialisation Strategy For Lbl-Technology®-Based Drug Delivery Systems; Business Summary; How Nanoparticles Add Value For Investors In Drug Delivery Companies; Commercialisation Strategy; Case Study -- Access Pharmaceuticals’ Product Pipeline For Cobalamin™- Mediated Disease Targeting; Business Summary; Technology Core Competency; How Nanoparticle Add Value For Investors In Drug Delivery Comp; Case Study - Azaya Therapeutics’ Product Pipeline For Protein Stabilized Liposome (Psl™) Nanotechnology; Business Summary; Technology Core Competency; Commercialisation Strategy
NANOPARTICLE DRUG DELIVERY SYSTEM BY DELIVERY METHOD/ROUTES OF ADMINISTRATION
DELIVERY METHOD
ORAL ADMINISTRATION: Case Study -- Access Pharmaceuticals’ Cobalamin™ - Mediated Disease Target; Case Study - Nanotherapeutics’ Nanoparticle Oral Applications; Case study - SoluBest’s Solumer™ Technology Platform
TRANSDERMAL DELIVERY: Case Study -- Biophan Technologies’ Transdermal Patches By Using Halloysite Nanotubes Technology; Case Study -- The Interstitial NanoSystems’ Transdermal Nanoparticle Delivery
INJECTABLE DELIVERY: Case Study -- Biophan Technologies’ Nanomagnetic Guided Drug Delivery; Case Study -- Nanobiotix’s NanoBiodrugsTM
TOPICAL DELIVERY: Case Study -- Starpharma’s VivaGel™; Case Study - Nanotherapeutics’ NanoDRY™; NanoCOAT™ and NanoQUAD™ Drug Delivery Systems
INHALED/NASAL/PULMONARY DELIVERY: Case Study -- Interstitial NanoSystem’s Pulmonary Nanoparticle Delivery
IMPLANTABLE DELIVERY: Case Study -- Biophan Technologies’ Nanomagnetic Drug Delivery: Drug-Eluting Implanted Devices; Case Study -- NanoBioMagnetics’ Organ-Assisting-Device (OAD) Technologies
NANOPARTICLE DRUG DELIVERY SYSTEM BY THERAPEUTIC
AREA
CANCER THERAPY: Case Study -- Nanocarrier’s Micellar Nanoparticles And Key Delivery Systems; Case Study -- Abraxis BioScience’s Nanoparticle Albumin Bound (nabTM) Technology Platform; Case Study -- Abraxis BioScience’s Abraxane®; Case Study -- Access Pharmaceuticals, Inc.’s Nanoparticle Aggregate Drug Delivery Technology; Case Study -- Access Pharmaceuticals’ ProLindac™; Case Study -- Advance Nanotechnologies’ Nanoparticle Composites Drug Delivery System; Case Study -- BioAlliance Pharma’s Nanoparticle-based Transdrug® Drug Delivery Platform; Case Study -- Cornerstone Pharmaceuticals’ Emulsiphan™ Nanoparticle Tumor Targeting Technology; Case Study -- Insert Therapeutics’ Nanoparticle Mediated Drug Delivery System; Case Study -- Keystone Nano’s Molecular Dots (MDs) Drug Delivery Technology; Case Study -- Magforce Nanotechnologies’ MagForce® Nanoparticles; Case Study -- Tempo Pharmaceuticals’ Nanocell™ Technology; Case Study -- Aphios Corporation’s TaxosomesTM
VACCINES: Case Study -- Biosante Pharmaceuticals’ Calcium Phosphate Nanoparticles (CAP)-based Technology; Case Study -- NanoMed's Nanotemplate Engineering Technology; Case Study -- Novavax’s Micellar Nano Particles (MNPs), Novasome® Paucilamellar Vesicles And Virus-Like Particle (VLP) Technology
ANTIBODY: Case Study -- Ablynx’s Nanobody® Platform; Case Study - NanoViricides’ Targeted Anti-Viral Therapeutics Platform
DNA BASED THERAPY: Case Study -- Introgen Therapeutics’ Nanoparticle Drug Delivery Technology Platform; Case Study -- Asklêpios BioPharmaceutical Inc.’s Biological Nano Particles (BNP™) Platform; Case Study -- Copernicus Therapeutics’ DNA Nanoparticles; Case Study -- Calando Pharmaceuticals’ Targeted Polymeric Nanoparticle Delivery Systems And Sirna Design; Case Study -- Epeius Biotechnologies’ Targeted Delivery System (TDS) Technology; Case Study -- Intradigm’s Nanoparticle-Based Delivery System; Case Study -- Flamel Technologies’ Medusa® Delivery Platform; Case Study -- Novosom AG’s SMARTICLES® and CAGICLES® Technology; Case Study -- Transgenex Nanobiotech’s SiPlex™ Technology
NANOPARTICLE DRUG DELIVERY SYSTEM BY TECHNOLOGY
NANOPARTICULATE ENCAPSULATION: Case Study -- Aquanova’s Nanoparticulate Encapsulation Technology; Case Study -- Bio Delivery Sciences International’s Bioral® Encochleation Drug Delivery Technology; Case Study -- Capsulution’s LBL-Technology®-based Drug Delivery Systems; Case Study -- Ceramisphere’s Encapsulation Technology; Case Study - Genesegues’ Targeted Nanocapsule Technology; Case Study - iCeutica’s Encapsulated Organic Nanoparticles (EON™) Platform; Case Study - NutraLease’s Nanoencapsulation Technology
THE DENDRIMER-BASED TARGETED THERAPEUTICS
TECHNOLOGY: Case Study -- Avidimer Therapeutics’ Avidimers; Case Study -- Dendritic Nanotechnologies Inc. (DNT)’S Priostar™ Dendrimer Nanotechnology
LIPOSOMES NANOTECHNOLOGY: Case Study -- Azaya Therapeutics’ Protein Stabilized Liposome (PSL) Nanotechnology Platform; Case Study -- LiPlasome Pharma’s Liposome-based Drug Delivery Platform
NANOTUBE TECHNOLOGIES: Case Study -- Biophan Technologies’ Halloysite Nanotube Technologies; Case Study -- NanoCyte’s Nanotube Technology-based Drug Delivery System
NANOSHELL TECHNOLOGY: Case Study -- Nanospectra Biosciences’ AuroLase™ Cancer Therapy
NANOPARTICLES COATING TECHNOLOGY: Case Study -- Cytimmune’s Colloidal Gold Nanoparticle-Based Delivery Platform
SILICA-CHITOSAN NANOCOMPOSITE: Case Study -- ISTN’s Silica-Chitosan Nanocomposties For Peptic Ulcer Treatment
NANOCRYSTAL TECHNOLOGY: Case Study -- Elan’s NanoCrystal® Technology
NANOSOME TECHNOLOGY: Case Study -- Molecular Therapeutics’ Nanosome Platform
NANOSUSPENSION TECHNOLOGY: Case Study -- Baxter BioPharma Solutions’ NANOEDGE Dispersion Technology
POLYMER THERAPEUTICS: Case Study - Labopharm’s Polymeric Nano-Delivery System™; Case Study -- Intezyne Technologies’ IVECT™ Drug Delivery Platform (DDP); Case Study -- Insert Therapeutics’ Nanoparticle Mediated Drug Delivery System
APPENDIX 1: LIST OF NANOPARTICLE DRUG DELIVERY PLATFORMS/TECHNOLOGIES
APPENDIX 2: NANOPARTICLES IN DRUG DELIVERY PRODUCTS ON THE MARKET OR IN CLINICAL TRIALS
APPENDIX 3: OVERVIEW OF NANOPARTICLE APPLICATIONS IN DRUG DELIVERY
APPENDIX 4: DRUG DELIVERY COMPANY - COMPANIES WHO PRODUING NANOPARTICLES/TECHNOLOGIES ENABLE BETTER DRUG DELIVERY COMPOUNDS
APPENDIX 5: DRUG FORMULATION COMPANY - COMPANIES WHO USING NANOPARTICLE-ENABLED FORMULATIONS TO ENHANCE DRUG DELIVERY

Abstract

The report projects that the total market for nanotechnology-enabled drug delivery will rise to $26 billion by 2012 from its current size of $3.39 billion, representing a compound annual growth rate of 37%. But this is just the beginning; the market could steeply rise after 2012, reaching potentially $220 billion by 2015 for these nano-enabled compounds. With such enormous growth anticipated, the 300-page report examines over 60 different companies, including 38 drug formulation companies and 23 drug delivery companies, analyzing where they are in their product pipeline, the available market, and the value that their products add to drug delivery. With 58 case studies of nanoparticle drug delivery platforms and technologies summaries, it becomes possible both for investors and companies in the pharmaceutical industry to understand how nanotechnologies will impact the drug delivery market and the companies in the best position to exploit this growth.

Nanotechnologies have already begun to change the scale and methods of drug delivery and hold huge potential for future developments in this area. New formulations and routes for drug delivery have the potential to broaden the therapeutic potential of administered treatments by allowing the delivery of new types of medicine to previously inaccessible sites in the body. In contrast to developing completely new drug compounds, introducing upgraded formulations greatly reduces the risk, time and capital invested in new drug development. Nanoparticle drug delivery technology can enable reformulation of existing drugs to increase product lifecycle, increase profitability, expand intellectual property estate and discourage competition during a drug’s most valuable years.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

The Nanoparticle Drug Delivery Market

Table of Contents

Abstract